UltraCAR-T Therapy – Scope & Possibilities in Multiple Myeloma Management
Ongoing clinical trials are investigating the safety and efficacy of a new type of CAR T (Chimeric antigen receptor T-cells) therapy called UltraCAR-T therapy for myeloid malignancies. Unlike current CAR T cells, which utilize viruses to attach the CAR to the T cells, UltraCAR-T uses a non-viral gene delivery system and has a rapid turnaround compared to traditional CAR-T cells manufacturing process. We are talking to Dr. David Sallman, a hematologist in the Malignant Hematology Program at Moffitt Cancer Center to learn more about the new type of CAR-T cells, their action, side effects and scope of their use for treatment of multiple myeloma.
CureTalks is an online Talk featuring a leading expert in conversation with a panel and the audience. The audience can ask questions from the panelists LIVE on the talk by dial-ing in. To hear the talk via phone or on-line, please add your email on the left; we will send you Live Talk access details. You can also write your questions in the Comments/Questions section below and your question maybe selected to be featured on the talk.